Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30, 2025 – PRISM MediaWire – BioStem Technologies Inc.
BioStem Technologies to Present at the Centri Capital Conference
The presentation will be webcast at 10:30 AM ET on April 22, 2025 POMPANO BEACH, Fla., April 21, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies, Inc. (BSEM) Q4 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q4 2024 Earnings Conference Call April 14, 2025 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Officer Michael Fortunato - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Erik Voss - Mission Vertical Mitchell Sacks - Grand Slam Richard Huebner - GVC Capital Operator Please stand by.
BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025
Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 08, 2025 – PRISM MediaWire – BioStem Technologies Inc.
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
POMPANO BEACH, Fla., April 1, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
The presentation will be webcast at 1:30 PM ET on April 10, 2025 POMPANO BEACH, Fla., March 27, 2025 – BioStem Technologies, Inc.
BioStem Technologies: Building On Advanced Wound Care Needs
BioStem Technologies' falling share price and rising earnings present a growth opportunity, supported by strong Q4 results, new products, and a potential NASDAQ listing. Q4-2024 revenue expected to rise 794% YoY, with full-year net revenue increasing 1,702%, driven by robust product adoption and strategic partnerships. Despite operational success, BioStem's stock remains undervalued; a one-year price target of $17.22 reflects a 60.13% increase from its current price.
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
Study comparing BioStem's proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion POMPANO BEACH, FL, February 24, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
POMPANO BEACH, Fla., January 13, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024.
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies CEO to Present at Biotech Showcase 2025
Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Florida, January 2, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
